{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:30:57Z","timestamp":1790951457173,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12967-019-2033-x","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T05:03:56Z","timestamp":1566968636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-3821","authenticated-orcid":false,"given":"Luca","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Perrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Piai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia Clara","family":"Pafundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Nevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Monari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Miglioresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Guerrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando Carlo","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Morisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Izzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Elio","family":"Adinolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"2033_CR1","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","volume":"62","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87\u201399.","journal-title":"J Hepatol"},{"key":"2033_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12072-017-9805-2","volume":"11","author":"J Shi","year":"2017","unstructured":"Shi J, Li Y, Chang W, Zhang X, Wang FS. Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatol Int. 2017;11:374\u201383.","journal-title":"Hepatol Int"},{"key":"2033_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3109\/00365520903428614","volume":"45","author":"A Perrella","year":"2010","unstructured":"Perrella A, Sbreglia C, Atripaldi L, Esposito C, D\u2019Antonio A, Perrella O. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scand J Gastroenterol. 2010;45:250\u20135.","journal-title":"Scand J Gastroenterol"},{"key":"2033_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.antiviral.2017.08.016","volume":"146","author":"MH Van der Ree","year":"2017","unstructured":"Van der Ree MH, Stelma F, Willemse SB, Brown A, Swadling L, van der Valk M, et al. Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Antiviral Res. 2017;146:139\u201345.","journal-title":"Antiviral Res"},{"key":"2033_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cellimm.2017.08.004","volume":"326","author":"XJ Hou","year":"2018","unstructured":"Hou XJ, Ye F, Li XY, Liu WT, Jing YY, Han ZP, et al. Immune response involved in liver damage and the activation of hepatic progenitor cells during liver tumorigenesis. Cell Immunol. 2018;326:52\u20139.","journal-title":"Cell Immunol"},{"key":"2033_CR6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdw219","volume":"27","author":"TC Wirth","year":"2016","unstructured":"Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016;27:1467\u201374.","journal-title":"Ann Oncol"},{"key":"2033_CR7","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1053\/j.gastro.2012.01.045","volume":"142","author":"SM Lemon","year":"2012","unstructured":"Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012;142:1274\u20138.","journal-title":"Gastroenterology"},{"key":"2033_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.28535","volume":"64","author":"HB El-Serag","year":"2016","unstructured":"El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64:130\u20137.","journal-title":"Hepatology"},{"key":"2033_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","volume":"155","author":"P Nahon","year":"2018","unstructured":"Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, ANRS CO12 Cir Vir group, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155:1436\u201350.","journal-title":"Gastroenterology"},{"key":"2033_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig M, Mari\u00f1o Z, Perell\u00f3 C, I\u00f1arrairaegui M, Ribeiro A, Lens S, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;65:719\u201326.","journal-title":"J Hepatol"},{"key":"2033_CR11","first-page":"e748","volume":"3","author":"L Rinaldi","year":"2016","unstructured":"Rinaldi L, Di Francia R, Coppola N, Guerrera B, Imparato M, Monari C, et al. Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings. WCRJ. 2016;3:e748.","journal-title":"WCRJ"},{"key":"2033_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol. 2016;65:727\u201333.","journal-title":"J Hepatol"},{"key":"2033_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jhep.2016.06.009","volume":"65","author":"K Kozbial","year":"2016","unstructured":"Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol. 2016;65:856\u20138.","journal-title":"J Hepatol"},{"key":"2033_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","volume":"69","author":"A Romano","year":"2018","unstructured":"Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol. 2018;69:345\u201352.","journal-title":"J Hepatol"},{"key":"2033_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","volume":"155","author":"V Calvaruso","year":"2018","unstructured":"Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Rete Sicilia Selezione Terapia-HCV (RESIST-HCV), et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018;155:411\u201321.","journal-title":"Gastroenterology"},{"key":"2033_CR16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer","year":"2012","unstructured":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908\u201343.","journal-title":"J Hepatol"},{"key":"2033_CR17","unstructured":"Associazione Italiana per lo Studio del Fegato. Documento di indirizzo dell\u2019Associazione Italiana per lo Studio del Fegato per l\u2019uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammesse alla rimborsabilit\u00e0 in Italia. http:\/\/webaisf.org\/documento-hcv-2018\/ ."},{"key":"2033_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"European Association for Study of Liver","year":"2015","unstructured":"European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199\u2013236.","journal-title":"J Hepatol"},{"key":"2033_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-0030-1247133","volume":"30","author":"A Forner","year":"2010","unstructured":"Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61\u201374.","journal-title":"Semin Liver Dis"},{"key":"2033_CR20","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1136\/gut.2006.099887","volume":"55","author":"A Perrella","year":"2006","unstructured":"Perrella A, Vitiello L, Atripaldi L, Conti P, Sbreglia C, Altamura S, et al. Elevated CD4+\/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut. 2006;55:1370\u20131.","journal-title":"Gut"},{"key":"2033_CR21","first-page":"776","volume":"12","author":"RS Brown Jr","year":"2016","unstructured":"Brown RS Jr. The possible association between DAA treatment for HCV infection and HCC recurrence. Gastroenterol Hepatol. 2016;12:776\u20139.","journal-title":"Gastroenterol Hepatol"},{"key":"2033_CR22","doi-asserted-by":"publisher","first-page":"e3017","DOI":"10.1038\/cddis.2017.395","volume":"8","author":"R Critelli","year":"2017","unstructured":"Critelli R, Milosa F, Faillaci F, Condello R, Turola E, Marzi L, et al. Microenvironment inflammatory infiltrate drive growth speed and outcome of hepatocellular carcinoma: a prospective clinical study. Cell Death Dis. 2017;8:e3017.","journal-title":"Cell Death Dis"},{"key":"2033_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41395-018-0062-3","volume":"113","author":"A Perrella","year":"2018","unstructured":"Perrella A, Rinaldi L, Galeota-Lanza A, Izzi A. DAAa and long term clinical outcome in hepatitis C: the panacea for all diseases still does not exsist. Am J Gastroenterol. 2018;113:1251\u201366.","journal-title":"Am J Gastroenterol"},{"key":"2033_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2017.10.035","volume":"154","author":"JD Debes","year":"2018","unstructured":"Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with hcv infection treated with direct-acting antivirals. Gastroenterology. 2018;154:515\u20137.","journal-title":"Gastroenterology"},{"key":"2033_CR25","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/hep.29911","volume":"68","author":"F Faillaci","year":"2018","unstructured":"Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, Turola E, et al. Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals. Hepatology. 2018;68:1010\u201324.","journal-title":"Hepatology"},{"key":"2033_CR26","first-page":"421","volume":"13","author":"S Grandhe","year":"2017","unstructured":"Grandhe S, Frenette CT. Occurrence and recurrence of hepatocellular carcinoma after successful direct-acting antiviral therapy for patients with chronic hepatitis C virus infection. Gastroenterol Hepatol. 2017;13:421\u20135.","journal-title":"Gastroenterol Hepatol"},{"key":"2033_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imm.12005","volume":"137","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi T, Nakatsuka K, Shimizu M, Tamura H, Shinya E, Atsukawa M, et al. Ribavirin modulates the conversion of human CD4(+)CD25(\u2212) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Immunology. 2012;137:259\u201370.","journal-title":"Immunology"},{"key":"2033_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22007","author":"J Tan","year":"2018","unstructured":"Tan J, Ye J, Song M, Hu Y. Ribavirin augments doxorubicin\u2019s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018. https:\/\/doi.org\/10.1002\/jbt.22007 .","journal-title":"J Biochem Mol Toxicol"},{"key":"2033_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrc1934","volume":"6","author":"PA Farazi","year":"2006","unstructured":"Farazi PA, De Pinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674\u201387.","journal-title":"Nat Rev Cancer"},{"key":"2033_CR30","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1128\/AAC.01253-16","volume":"60","author":"M Fenaux","year":"2016","unstructured":"Fenaux M, Lin X, Yokokawa F, Sweeney Z, Saunders O, Xie L, et al. Antiviral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive of increased in vivo mitochondrial toxicity risk. Antimicrob Agents Chemother. 2016;60:7077\u201385.","journal-title":"Antimicrob Agents Chemother"},{"key":"2033_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.antiviral.2017.04.005","volume":"143","author":"Z Jin","year":"2017","unstructured":"Jin Z, Kinkade A, Behera I, Chaudhuri S, Tucker K, Dyatkina N, Rajwanshi VK, et al. Structure\u2013activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Res. 2017;143:151\u201361.","journal-title":"Antiviral Res"},{"key":"2033_CR32","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/lt.20472","volume":"11","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, et al. Tumor predicts vascular invasion and histologic grade: implications for selection of surgical treatment for size hepatocellular carcinoma. Liver Transpl. 2005;11:1086\u201392.","journal-title":"Liver Transpl"},{"key":"2033_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12893-016-0135-4","volume":"16","author":"X Wang","year":"2016","unstructured":"Wang X, Wang Z, Wu L. Combined measurement of tumor number and size helps estimate the outcome of resection of Barcelona clinic liver cancer stage B hepatocellular carcinoma. BMC Surg. 2016;16:22.","journal-title":"BMC Surg"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-2033-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:27:48Z","timestamp":1664213268000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-2033-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2033"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-2033-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"20 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"University of Campania Luigi Vanvitelli Ethic Committee (protoc. number 647).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Non individual data is shown.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent approval"}},{"value":"The authors declare that they have no actual or potential competing interests, including any financial aspects, personal or other relationships with other people or organizations within it that may not be appropriate influence (prejudices) on their work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}